Suppr超能文献

高级别浆液性卵巢癌长期幸存者的生存条件概率及预后因素

Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer.

作者信息

Fabbro Michel, Colombo Pierre-Emmanuel, Leaha Cristina Marinella, Rouanet Philippe, Carrère Sébastien, Quenet François, Gutowski Marian, Mourregot Anne, D'Hondt Véronique, Coupier Isabelle, Vendrell Julie, Vilquin Paul, Pujol Pascal, Solassol Jérôme, Mollevi Caroline

机构信息

Medical Oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, 3429834090 Montpellier, France.

Surgical Oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, 34298 Montpellier, France.

出版信息

Cancers (Basel). 2020 Aug 5;12(8):2184. doi: 10.3390/cancers12082184.

Abstract

High-grade serous ovarian cancers (HGSOC) are heterogeneous, often diagnosed at an advanced stage, and associated with poor overall survival (OS, 39% at five years). There are few data about the prognostic factors of late relapses in HGSOC patients who survived ≥five years, long-term survivors (LTS). The aim of our study is to assess the probability of survival according to the already survived time from diagnosis. Data from HGSOC patients treated between 1995 and 2016 were retrospectively collected to estimate the conditional probability of survival (CPS), probability of surviving Y years after diagnosis when the patient had already survived X years, and to determine the LTS prognostic factors. The primary endpoint was OS. 404 patients were included; 120 of them were LTS. Patients were aged 61 years (range: 20-89), WHO performance status 0-1 in 86.9% and 2 in 13.1%, and Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging III and IV in 82.7% and 17.3% patients. Breast cancer (BRCA) status was available in 116 patients (33% mutated), including 58 LTS (36% mutated). No macroscopic residual disease was observed in 58.4% patients. First-line platinum-based chemotherapy plus paclitaxel was administered in 80.4% of patients (median: six cycles (range: 1-14)). After a 9 point 3-year follow-up, median OS was four years (95% CI: 3.6-4.5). The CPS at five years after surviving one year was 42.8% (95% CI: 35.3-48.3); it increased to 81.7% (95% CI: 75.5-87.8) after four survived years. Progression-free interval>18 months was the only LTS prognostic factor in the multivariable analysis (hazard ratio (HR) = 0.23; 95% CI: 0.13-0.40; < 0.001). The CPS provided relevant and encouraging clinical information on the life expectancy of HGSOC patients who already survived a period of time after diagnosis. LTS prognostic factors are useful for clinicians and patients.

摘要

高级别浆液性卵巢癌(HGSOC)具有异质性,通常在晚期被诊断出来,且总体生存率较差(5年生存率为39%)。对于存活≥5年的HGSOC患者(长期幸存者,LTS),关于晚期复发的预后因素的数据很少。我们研究的目的是根据自诊断以来已存活的时间评估生存概率。回顾性收集了1995年至2016年期间接受治疗的HGSOC患者的数据,以估计生存条件概率(CPS),即患者已存活X年时诊断后存活Y年的概率,并确定LTS的预后因素。主要终点是总生存期(OS)。纳入了404例患者;其中120例为LTS。患者年龄为61岁(范围:20 - 89岁),86.9%的患者世界卫生组织(WHO)体能状态为0 - 1,13.1%为2;82.7%的患者国际妇产科联合会(FIGO)分期为III期,17.3%为IV期。116例患者(33%发生突变)可获得乳腺癌(BRCA)状态,其中58例LTS(36%发生突变)。58.4%的患者未观察到肉眼可见的残留病灶。80.4%的患者接受了一线铂类化疗加紫杉醇(中位:6个周期(范围:1 - 14))。经过9.3年的随访,中位OS为4年(95%置信区间:3.6 - 4.5)。存活1年后5年的CPS为42.8%(95%置信区间:35.3 - 48.3);存活4年后增至81.7%(95%置信区间:75.5 - 87.8)。无进展生存期>18个月是多变量分析中唯一的LTS预后因素(风险比(HR)= 0.23;95%置信区间:0.13 - 0.40;P < 0.001)。CPS为已在诊断后存活一段时间的HGSOC患者的预期寿命提供了相关且令人鼓舞的临床信息。LTS预后因素对临床医生和患者有用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e380/7465919/731cd1f76e45/cancers-12-02184-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验